Accueil   Diary - News   All news Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference

Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference

  • Presentation highlighted different stereoisomer properties of pioglitazone and other thiazolidinediones (TZDs)
  • Data observed suggests a more favorable profile for PXL065 versus pioglitazone and other TZDs for the treatment of NASH

 

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that an oral presentation, including data for PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, was made at the 2019 NASH-TAG Conference. The presentation titled “PXL065, Pioglitazone (pio), and Thiazolidinediones (TZDs): Unravelling Pio’s superior efficacy for NASH and role of stereoisomers” was given on January 5, 2019 in Park City, Utah.

 

 

Read the press release